Citryll

Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases.

Citryll is pioneering an innovative approach to immune mediated inflammatory diseases. Targeting ETs as a fundamental but previously unaddressed driver of inflammation, Citryll is going beyond individual pathway management and symptom treatment to reduce inflammation at its core. By targeting ET biology, Citryll aims to establish a new class of therapeutics designed to deliver broader and more durable disease control.

Citryll’s lead asset, CIT-013, targets ETs via a dual mechanism of action, inhibiting the formation of new ETs and enhancing the clearance of existing ETs. This is achieved through selective binding to citrullinated histones. By selectively binding extracellular targets and not entering cells, CIT-013 is designed to minimize off-target effects while preserving normal cellular function. Through its dual mechanism and upstream positioning, CIT-013 has the potential to become a cornerstone therapy across multiple immune-mediated inflammatory diseases.

While many current therapies target individual cytokines or receptors, Citryll’s approach addresses a shared driver of inflammation. Citryll’s targeted approach has applications in many inflammatory diseases. Its current focus is on rheumatoid arthritis and hidradenitis suppurativa, with clinical development programs underway for both diseases. Citryll has the potential to create a new class of therapeutics for a wide range of immune-mediated inflammatory diseases.